COPD is one of the nation’s most serious health problems, affecting over 24 million Americans. The condition created direct and indirect costs of nearly $50 billion in 2010, according to the American ...
Nucala's growth is driven by a strong commercial base, expansion into COPD treatment after U.S. and European approvals, and a diversified multi-indication use including asthma and nasal polyps. This ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation, a leader in therapeutic pulmonary device technologies, announced today that UnitedHealthcare®, the largest commercial insurer in the United ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results